Información del artículo
El Texto completo está disponible en PDF
Bibliograf¿a
[1]
Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells. Circ Res. 2006; 99:924-32.
[2]
Antioxidants: the good, the bad and the ugly. Can J Cardiol. 2006; 22(Suppl B):61B-5B.
[3]
A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med. 2006; 44:1052-9.
[4]
Human paraoxonase: a promisingapproach for pre-treatment and therapy of organophosphorous toxicity. Toxicology. 2007; 233:47-59.
[5]
Importancia clínico-biológica de las paraoxonasas. Clin Invest Arterioscl. 2007; 19(Supl 4):20-5.
[6]
Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, et al. Arterioscler Thromb Vasc Biol. 2002;22:1329-33.
[7]
Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem. 2003; 49:1491-7.
[8]
Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Invest. 2007; 37:187-96.
[9]
Análisis de la actividad paraoxonasa (PON1) y de los polimorfismos PON1 192 y PON1 55 en la población prepuberal del Estudio Cuatro Provincias. Clin Invest Arterioscler. 2007; 19:287-92.
[10]
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991; 86:193-9.
[11]
Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem. 2002; 48:261-8.
[12]
Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2005; 44:6371-82.
[13]
Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol. 2006; 45:51-9.
[14]
Comparison of paraoxonase- 1 measurements in serum and in lithium-heparin-anticoagulated plasma samples. Clin Chem. 2005; 51:922-3.
[15]
Paraoxonase prevents accumulation of lipoperoxides in low-density lipoproteins. FEBS Lett. 1991; 286:152-4.
[16]
Para-- oxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun. 2004; 318:680-3.
[17]
Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res. 2007; 100:1200-7.
[18]
Rull A, Escolà-Gil JC, Julve J, et al. Deficiency in monocyte chemoattractant protein-1 modifies lipid and glucose metabolism. Exp Mol Pathol. En prensa. doi: 10.1016/j.yexmp.2007.03.003.